Madison Area Lyme Support Group

Please see the following letter sent to all winners of the LymeX prize…

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “contact@steveandalex.org” <contact@steveandalex.org>
Cc: The Tick-Borne Disease Working group and all winners of the LymeX prize
Date: 11/30/2022 1:12 PM
Subject: LymeX prize competition announces ten Phase 1 winners

November 7, 2022

LymeX prize competition announces ten Phase 1 winners
https://www.lymedisease.org/lymex-phase-one-winners/

“The ultimate goal of the multiphase competition is to nurture the development of diagnostics toward Food and Drug Administration review.” 

To all winners of the Phase 1 LymeX Diagnostics Prize competition,

After spending the last thirteen years studying the mishandling of Lyme disease, I felt compelled to share the following facts (and supporting documentation) regarding prior attempts to introduce “new and/or improved” diagnostic detection methods. I concluded that a chronic relapsing seronegative disease does not fit the business model of vaccine development, patent royalties and pharmaceutical profits so laboratory confirmation of persistent infection after antibiotic treatment must be squelched/suppressed at all costs.

Examples

1. Culture: Advanced Laboratory Services

Barbara J.B. Johnson, microbiologist with the Centers for Disease Control and Prevention claimed laboratory contamination in reference to positive test results (Chronic Lyme) found in Advanced Laboratory Services’ Borrellia culture test. If this is the case, why didn’t the CDC work with Advanced Laboratory Services to perfect its culture test and resolve the so-called “contamination” issues?

New Lyme Culture Test Failed CDC Analysis Aug 20, 2013
http://www.medscape.com/viewarticle/809626

New CDC/FDA Warning Against Unapproved Lyme Culture Test
https://www.medscape.com/viewarticle/823840

“Dr. Nelson emphasized that for Lyme disease diagnosis, the CDC recommends a 2-step process of serologic testing: first, an FDA-cleared enzyme immunoassay, followed in immunoassay-positive or equivocal cases by confirmatory Western blot. Only patients positive on both tests are considered to have Lyme disease.”

Carl Tuttle’s comment: Current FDA approved Lyme disease tests (Antibody tests) cannot be used to gauge treatment failure or success which makes them ideal for concealing an antibiotic resistant/tolerant superbug allowing the thirty-year-old dogma to remain intact.

2. PCR testing:

We have seen similar actions from the CDC with PCR testing as well. In May of 2012 the CDC announced the Development of a Novel Genus-specific Real-time PCR Assay for Detection and Differentiation of Bartonella Species and Genotypes:  http://www.ncbi.nlm.nih.gov/pubmed/22378904

Here the CDC is using PCR for a definitive diagnosis of Bartonella however, according to the CDC and the ALDF group on June 11, 2012 PCR cannot be used for Lyme diagnosis per the CDC expert commentary posted on Medscape below:

PCR for Diagnosis of Lyme Disease: Is It Useful? Christina A. Nelson, MD, MPH
https://www.medscape.com/viewarticle/764501

Quotes from Christa Nelson: (Medical Officer in the Bacterial Diseases Branch of CDC’s Division of Vector-Borne Disease)

“Is PCR useful for the diagnosis of Lyme disease? In general, the answer is no.”

“Two-tiered serology remains the mainstay of laboratory testing for Lyme disease.”

Carl Tuttle’s comment: PCR is acceptable for Bartonella but not Lyme disease. Double standard here?

3. Nested PCR and DNA sequencing: Milford Molecular Diagnostics

In September of 2012 the CDC entered into an agreement with Dr. Sin Lee to evaluate the viability of his DNA sequencing technology. Martin E. Schriefer, Ph.D., the chief of the CDC’s diagnostic and reference laboratory, stated the following: (from the attached court document)  https://www.dropbox.com/s/8irsb6oqunwy3zq/Notice%20of%20Appeal.pdf?dl=0

“So wherever possible we encouraged and required other non-serologic-based tests in addition to clinical presentation so that might have included PCR or culture or both. . . . And again I’m looking forward to seeing a greater utilization of PCR as a diagnostic tool in the future.” -Martin E. Schriefer, Ph.D.

When Dr. Lee published a case of persistent infection (Chronic Lyme disease) in 2014 all communication with the CDC ended abruptly with no explanation.

DNA Sequencing Diagnosis of Off-Season Spirochetemia with Low Bacterial Density in Borrelia burgdorferi and Borrelia miyamotoi Infections  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4139787/

Carl Tuttle’s Comment: It should be noted that the chronic Lyme disease case identified in this publication was found in blind-coded serum samples sent to Dr. Lee’s laboratory from the CDC’s Lyme disease serum repository and other species of Borrelia were found within these samples using DNA sequencing; the CDC had no idea that multiple pathogens were involved.

Has the CDC purposely discredited other innovative technologies which are in competition to the invention being patented by Theresa M. Russell and Barbara J.B. Johnson of the NCEZID under Pub. No. WO 2013110026 A1 entitled “Compositions and methods relating to Lyme disease”?

Dr. Lee although participated in the competition, was not awarded the LymeX prize. Does anyone believe that this decision was just a coincidence?

4. NIST

New Experimental Test Detects Signs of Lyme Disease Near Time of Infection February 11, 2016
https://www.nist.gov/news-events/news/2016/02/new-experimental-test-detects-signs-lyme-disease-near-time-infection

“The current standard blood test for Lyme disease exposes the infection only after antibodies have accumulated to detectable levels, which can take up to 4 to 6 weeks. If patients exhibit a telltale bull’s-eye rash, diagnosis and treatment can begin earlier. But the rash does not occur in 20 to 30 percent of Lyme disease patients, according to the Centers for Disease Control and Prevention.

Rather than waiting for an infected person’s immune system to produce noticeable amounts of antibodies, the team chose to home in on the bacteria itself—specifically, proteins the bug sheds when attacked by the body’s defenses.

“From many candidates, we chose one that is both easily distinguished from human serum proteins and an unambiguous indicator of the bacteria,” Turko says. “This protein, which resides on the outer surface of membranes, became the target of our search in serum samples.”

Carl Tuttle’s comment: Response from Dr Illarion Turko; “This project did not receive further development and is on-hold for now.”

So, who at the CDC got to Dr. Turko and discouraged further development?

Other examples of interference/intimidation

In 2008 Nordin Zeidner published his study regarding single dose Doxycycline for tick bite. Pamela Weintraub interviewed Zeidner for her book:

Cure Unknown (Revised Edition): Inside the Lyme Epidemic

By Pamela Weintraub

https://books.google.com/books?id=

Excerpt:

“Immunologist Nordin Zeidner, chief of the CDC’s Vector-Host laboratory in Fort Collins, Colorado, told me internal agency studies had found the strategy questionable, and definitely ineffective in mice.”

“With the support of his CDC colleagues, Zeidner had begun to work with industry to develop an alternative: a form of injectable Doxy that could be sustained in the body for nineteen days.”

“Trying his formulation on mice, Zeidner found that 100 percent were protected from Lyme as well as the coinfection, anaplasmosis.”

“…..single dose doxy stopped Lyme disease not in 87% of mice, but rather, in 20 to 30 percent at most.”

_____________________________

Dr Gary Wormser of New York Medical College (who has controlled the Lyme disease narrative for the past three decades) published a study earlier promoting the use of single dose Doxy for tick bite. (See Wormser’s 2001 flawed NEJM article)

I understand that it was Wormser who called Zeidner’s superiors at the CDC to put an end to Zeidner’s work. Zeidner was told to discard the mice sera instead of testing for antibodies as he had promised.

Zeidner’s research was terminated for “lack of industrial support” Mead, and he was promoted, and his email address inactivated. The CDC stopped his research and sent him to Europe

I have attached Zeidner’s 2008 study for your review:

A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite
https://www.dropbox.com/s/jc0h9g9arjhc8l1/Zeidner%202008.pdf?dl=0

Questions for LymeX prize competition winners:

Are all of you confident that the current pandemic was handled properly by our Public Health Officials? Was diagnostic testing controlled/manipulated in any way? Have lifesaving therapies been suppressed over pharmaceutical profits (vaccines)?

I ask the competition winners to be suspect of HHS oversight for this LymeX prize competition and if any dishonest/suspicious activity is experienced as described previously in this letter, please seek early legal counsel, (perhaps collectively) and involve your state senators to expose the ongoing corruption hell bent at maintaining the false thirty-year Lyme disease narrative: “Lyme is Hard to Catch and Easily Treated” (with a 2-4wk antibiotic treatment mandated by the Infectious Diseases Society of America)

Respectfully submitted,

Carl Tuttle
Hudson, NH

Cc: All LymeX prize competition winners, All members of the 2022 Tick-Borne Disease Working Group, the Steven & Alexandra Cohen Foundation

More examples of interference/manipulation as reported through the experience of a clinician on the front lines:

2018 ILADS Webinar – History of Lyme Disease by Joseph J. Burrascano, Jr. MD. (Video Recording)
https://vimeo.com/306846706  Summary:

Joseph Burrascano, MD’s cogent history of Lyme: East Hampton, Long Island NY had the highest rate of Lyme in the world. 1965 internist Sidney Robin coined the term “Montauk Knee”.

1985   87 seronegative patients all had spirochetes produced using Alan McDonald’s culture technique. “Seronegativity is real”

@7:00  re: PTLDS – “There’s never, ever, ever been a description of this Post Lyme Syndrome from an immunological point of view that clarifies what it is and applies to every single patient”.

@9.05 Stony Brook study of 21 day doxycycline “… had a 100% FAILURE RATE… THEY KICKED ME OUT OF THE STUDY AFTER THAT; AND THEY NEVER REPORTED THOSE RESULTS.”

@9.35 Patient Evaluation: “I took advantage of Dr. McDonald’s culture… after treatment ended, if you waited a few weeks, they [patients] were all culture positive. It was failed treatment and a persistence of the infection.”

@12.45  Late 1980’s “Rocephin came onto the scene… 100% failure rate of 2 weeks of Rocephin, even at high dose… Duration of treatment is really, really what’s important.” Findings presented @ 1990 Stockholm International Conference.

@13.50  633 patient records reviewed indicated at least 4 months treatment for those “with multiple bites, Lyme arthritis, heart murmurs, hormonally active women, those sick for more than 1 year, age over 60, acute carditis, documented immune deficiency, failed oral treatment.”

@26.50 Discovered on lecture circuit Dr. Ed Masters from MO, John Druhl, NJ & Paul Levy, San Francisco all independently concluded higher doses and longer treatment necessary. They’d never met or communicated previously.

1990 NIH Gold Stain – 73 chronic patients, 13.5 months mean treatments. Discovered blebs and biofilms.

@31.19 “So, whatever happened to this great gold stain? Know what? Nothing. NIH stopped the funding… closed the whole thing down and never again did they ask front line Lyme doctors to contribute specimens to their studies. So, there’s some politics one more time.”

@32.58 Co infections seem to affect only chronic Lyme patients.

@34.19 Lyme is the thing that takes over the immune system, weakens our defenses….

@36.52 Lyme is an immune suppressive illness….

@38.25 McDonald presented cultures at “… a meeting of NYS Medical Society… detractors were people from Yale and Stony Brook who didn’t want their patented serologic tests to be usurped, and they started claiming that McDonald was falsifying his data and so forth.”